AU723891B2 - Human chemokine beta-11 and human chemokine alpha-1 - Google Patents

Human chemokine beta-11 and human chemokine alpha-1 Download PDF

Info

Publication number
AU723891B2
AU723891B2 AU61628/96A AU6162896A AU723891B2 AU 723891 B2 AU723891 B2 AU 723891B2 AU 61628/96 A AU61628/96 A AU 61628/96A AU 6162896 A AU6162896 A AU 6162896A AU 723891 B2 AU723891 B2 AU 723891B2
Authority
AU
Australia
Prior art keywords
seq
polypeptide
sequence
polypeptides
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU61628/96A
Other languages
English (en)
Other versions
AU6162896A (en
Inventor
Haodong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of AU6162896A publication Critical patent/AU6162896A/en
Application granted granted Critical
Publication of AU723891B2 publication Critical patent/AU723891B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
AU61628/96A 1995-06-05 1996-06-05 Human chemokine beta-11 and human chemokine alpha-1 Ceased AU723891B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46440195A 1995-06-05 1995-06-05
US46098795A 1995-06-05 1995-06-05
US08/464401 1995-06-05
US08/460987 1995-06-05
PCT/US1996/009572 WO1996039522A1 (en) 1995-06-05 1996-06-05 Human chemokine beta-11 and human chemokine alpha-1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU45079/00A Division AU750982B2 (en) 1995-06-05 2000-07-04 Human chemokine beta-11 and human chemokine alpha-1

Publications (2)

Publication Number Publication Date
AU6162896A AU6162896A (en) 1996-12-24
AU723891B2 true AU723891B2 (en) 2000-09-07

Family

ID=27039874

Family Applications (1)

Application Number Title Priority Date Filing Date
AU61628/96A Ceased AU723891B2 (en) 1995-06-05 1996-06-05 Human chemokine beta-11 and human chemokine alpha-1

Country Status (7)

Country Link
EP (1) EP0833914A4 (de)
JP (1) JPH11507224A (de)
KR (1) KR19990022283A (de)
CN (1) CN1190991A (de)
AU (1) AU723891B2 (de)
CA (1) CA2222280A1 (de)
WO (1) WO1996039522A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391589B1 (en) 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US6458349B1 (en) 1995-06-02 2002-10-01 Human Genome Sciences, Inc. Chemokine β-4 polypeptides
US5633149A (en) * 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6139832A (en) 1995-02-08 2000-10-31 Human Genome Sciences, Inc. Leukocyte adhesion inhibitor-1 (LAI-1) Polypeptides
AU750982B2 (en) * 1995-06-05 2002-08-01 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
WO1998011226A2 (en) * 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
EP0950066A1 (de) * 1996-10-04 1999-10-20 Human Genome Sciences, Inc. Therapeutisch wirksame zubereitungen und verfahren zur behandlung von erkrankungen mittels des leukozyten-adhaesions-inhibitor-1 (lai-1) und des chemokins beta-11 (ckbeta-11)
AU5410698A (en) * 1996-12-13 1998-07-03 Shionogi & Co., Ltd. Human cc chemokine elc
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6100387A (en) 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
JP2003521865A (ja) * 1997-10-24 2003-07-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １４８個のヒト分泌タンパク質
KR19990042713A (ko) * 1997-11-27 1999-06-15 허일섭 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법
US6110695A (en) * 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
CA2484121A1 (en) 2002-05-01 2003-11-13 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
BR112013005145B1 (pt) 2010-09-02 2022-02-15 Vaccinex, Inc Anticorpo isolado ou seu fragmento de ligação ao antígeno que se liga especificamente ao cxcl13, composição e uso de uma composição
WO2012068540A2 (en) 2010-11-19 2012-05-24 Toshio Imai Neutralizing anti-ccl20 antibodies
CA2865928C (en) 2012-03-02 2021-02-16 Vaccinex, Inc. Cxcl13 antagonist for the treatment of sjogren's syndrome
WO2014121053A1 (en) 2013-01-31 2014-08-07 Vaccinex, Inc. Methods for increasing immunoglobulin a levels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278287A (en) * 1989-05-12 1994-01-11 Genetics Institute, Inc. Human cytokine
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605817A (en) * 1995-01-19 1997-02-25 Incyte Pharmaceuticals, Inc. DNA encoding chemokine expressed in fetal spleen
AU1916795A (en) * 1995-02-08 1996-08-27 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278287A (en) * 1989-05-12 1994-01-11 Genetics Institute, Inc. Human cytokine
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins

Also Published As

Publication number Publication date
WO1996039522A1 (en) 1996-12-12
JPH11507224A (ja) 1999-06-29
CA2222280A1 (en) 1996-12-12
EP0833914A4 (de) 2003-05-28
AU6162896A (en) 1996-12-24
KR19990022283A (ko) 1999-03-25
CN1190991A (zh) 1998-08-19
EP0833914A1 (de) 1998-04-08

Similar Documents

Publication Publication Date Title
AU723891B2 (en) Human chemokine beta-11 and human chemokine alpha-1
US5986069A (en) Human haemopoietic maturation factor polypeptides
AU708903B2 (en) Human chemokine polypeptides
US7198944B2 (en) Human chemokine β-9 viral vectors
US6458349B1 (en) Chemokine β-4 polypeptides
AU713267B2 (en) Human chemokine beta-13
MXPA97008528A (en) Chemiosine bata-13 hum
WO1996024668A1 (en) Human chemokine beta-11 and human chemokine alpha-1
US5981230A (en) Polynucleotide encoding chemokine β-4
WO1996039520A1 (en) Human chemokine beta-12
US5866373A (en) Polynucleotide encoding a human chemotactic protein
US6537539B2 (en) Immune cell cytokine
US6908986B2 (en) Chemokine alpha 3
AU750982B2 (en) Human chemokine beta-11 and human chemokine alpha-1
AU753730B2 (en) Human chemokine beta-13
EP1006188B1 (de) Menschliche chemokin-polypeptide
US7393943B1 (en) Polynucleotides encoding a human chemotactic cytokine I
AU753088B2 (en) Human chemokine polypeptides
MXPA97009090A (en) Beta-11 human chemistry and chemisine alpha-1 hum
WO1997023640A1 (en) Human chemotactic cytokine i
CA2217216A1 (en) Human chemokine beta-13
EP0886642A1 (de) Immunzellencytokin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)